The protective effect of canagliflozin on renal function in obese patients with T2DM
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Canagliflozin (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 28 Dec 2017 Status changed from recruiting to discontinued.
- 15 Nov 2016 Status changed from not yet recruiting to recruiting.
- 04 Sep 2015 New trial record